NEW YORK, Aug. 12, 2021 /CNW/ — MindMed (Nasdaq: MNMD), (NEO: MMED), (DE: MMQ), a leading biotech company developing psychedelic-inspired therapies, has announced its quarterly financial results for the quarter ended June 30, 2021. Q2 2021 Financial Highlights (in USD) Total assets as of June 30, 2021 were $194 million, including $157 million in cash Net Cash Used in Operating Activities of $12…

Source

Previous articleBeckley Psytech completes oversubscribed $80m (£58m) fundraise to develop portfolio of psychedelic medicine breakthroughs
Next articleIn Awe: Psychedelic Assisted Psychotherapy and the Mystical Experience